A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Completed · Phase 3 · NCT02753127
Conditions: Colorectal Cancer
At a glance
- Research payments reported, 2025
- $13,474
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,253
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- Napabucasin (drug), Fluorouracil (drug), Leucovorin (drug), Irinotecan (drug), Bevacizumab (drug)
- Dates
- Started 2016-06; completion 2021-05-12
- Results posted
- Yes
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
From ClinicalTrials.gov, last updated 2023-11-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $13,474 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.